TY - JOUR
T1 - Treatment and Prognosis of Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear
T2 - A Multi-Institutional Retrospective Review of 87 Patients
AU - Ogawa, Kazuhiko
AU - Nakamura, Katsumasa
AU - Hatano, Kazuo
AU - Uno, Takashi
AU - Fuwa, Nobukazu
AU - Itami, Jun
AU - Kojya, Shizuo
AU - Nakashima, Torahiko
AU - Shinhama, Akihiko
AU - Nakagawa, Takashi
AU - Toita, Takafumi
AU - Sakai, Mitsuhiro
AU - Kodaira, Takeshi
AU - Suzuki, Mikio
AU - Ito, Hisao
AU - Murayama, Sadayuki
PY - 2007/8/1
Y1 - 2007/8/1
N2 - Purpose: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear. Methods and Materials: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61%) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39%). Results: The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55% and 54%, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83%, 55%, and 38%, respectively (p = 0.007). Conclusions: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.
AB - Purpose: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear. Methods and Materials: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61%) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39%). Results: The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55% and 54%, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83%, 55%, and 38%, respectively (p = 0.007). Conclusions: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.
UR - http://www.scopus.com/inward/record.url?scp=34547450063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547450063&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2007.01.052
DO - 10.1016/j.ijrobp.2007.01.052
M3 - Article
C2 - 17446002
AN - SCOPUS:34547450063
VL - 68
SP - 1326
EP - 1334
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
IS - 5
ER -